Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine

Experimental Biology and Medicine

Volumn 235, Issue 7, 2010, Pages 814-824

  Da Silva, Glenda Nicioli ^a   Marcondes, João Paulo De Castro ^a   De Camargo, Elaine Aparecida ^a   Passos Jr , Geraldo Aleixo Da Silva ^b   Sakamoto Hojo, Elza Tiemi ^b   Salvadori, Daisy Maria Fávero ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Apoptosis; Cisplatin; Gemcitabine; TP53; Urinary bladder transitional cell carcinoma

Indexed keywords

CISPLATIN; GEMCITABINE; PROTEIN P53;

APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DEATH; CELL SURVIVAL; CLONOGENIC ASSAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG CYTOTOXICITY; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; MUTANT; THERAPY EFFECT; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DEOXYCYTIDINE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; URINARY BLADDER NEOPLASMS;

EID: 77953771395     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2010.009322     Document Type: Article

References (55)

1. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM, Sesterhenn IA, Tachibana M, Weider J. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66:4-34
2. Pectasides D, Pectasides M, Economopoulos T. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer. Cancer Treat Rev 2006;32:456-70
3. Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006;27:361-73
4. Cordon-Cardo C. Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol Suppl 2008;218:154-65
5. Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 2000;89:630-9 (Pubitemid 30640110)
6. Olfert SM, Felknor SA, Delclos GL. An updated review of the literature: risk factors for bladder cancer with focus on occupational exposures. South Med J 2006;99:1256-63
7. Gallagher DJ, Milowsky MI, Bajorin DF. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer 2008;113:1284-93
8. Bellmut J, Albiol S, Ramirez de Olano A, Pujadas J, Maroto P. On behalf the Spanish oncology genitourinary group (SOGUG). Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium. Ann Oncol 2006;17:v113-17
9. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77
10. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602-8
11. Siddk ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistence. Oncogene 2003;22:7265-79
12. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev 2005;4:307-19
13. Nabhan C, Krett N, Gandhi V, Rosen S. Gemcitabine in hematologic malignancies. Curr Opin Oncol 2001;13:514-21
14. Bass AJ, Gockerman JP, Hammett E, De Castro CM, Adams DJ, Rosner GL, Payne N, Davis P, Foster T, Moore JO, Rizzieri DA. Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. J Clin Oncol 2002;20:2995-3000 (Pubitemid 34728895)
15. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001;15:875-90 (Pubitemid 32529886)
16. Toschi L, Finocchiaro G, Gioia V. Role of gemcitabine in cancer therapy. Fut Oncol 2005;1:7-17
17. Nishiyama H, Watanabe J, Ogawa O. p53 and chemosensitivity in bladder cancer. Int J Clin Oncol 2008;13:282-6
18. Kim E, Giese A, Deppert W. Wild type p53 in cancer cells: when a guardian turns into a blackguard. Biochem Pharmacol 2009;77:11-20
19. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 1998;292:435-45 (Pubitemid 28282455)
20. Kartalou M, Essgmann JM. Mechanism of resistance to cisplatin. Mutat Res 2001;478:23-43
21. Kannan K, Amariglio N, Rechavi G, Jakob-Hirsch J, Kela I, Kaminski N, Getz G, Domany E, Givol D. DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 2001;20: 2225-34 (Pubitemid 32531280)
22. Yip HT, Chopra R, Chkrabarti R, Veena MS, Ramamurthy B, Srivatsan ES, Wang MB. Cisplatin-induced growth arrest of head and neck cancer cells correlates with increased expression of p16 and p53. Arch Otolaryngol Head Neck Surg 2006;132:317-26
23. Andrews GA, Xi S, Pomerantz RG, Lin CJ, Gooding WE, Wentzel AL, Wu L, Sidransky D, Grandis JR. Mutation of p53 in head and neck squamous cell carcinoma correlates with BCL-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head Neck 2004;26:870-7 (Pubitemid 39299306)
24. Watanabe J, Nishiyama H, Okubo K, Takahashi T, Toda Y, Habuchi T, Kakehi Y, Tada M, Ogawa O. Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY. Urology 2004;63:989-93 (Pubitemid 38596702)
25. Chen M, Hough AM, Lawrence TS. The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization. Cancer Chemother Pharmacol 2000;45:369-74 (Pubitemid 30217160)
26. Cory AH, Cory JG. Gemcitabine-induced apoptosis in a drug-resistant mouse leukemia L1210 cell line that does not express p53. Adv Enzyme Regul 2004;44:11-25
27. Kielb SJ, Nikhil LS, Rubin MA, Sanda MG. Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer. J Urol 2001;166:482-7
28. Fechner G, Perabo FGE, Schmidt DH, Haase L, Ludwig E, Schueller H, Blatter J, Muller C, Albers P. Prelinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells. Urology 2003;61:468-73 (Pubitemid 36206567)
29. Rieger KM, Little AF, Swart JM, Kastrinakis WV, Fitzgerald JM, Hess DT, Libertino JA, Summerhayes IC. Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. Br J Cancer 1995;72:683-90
30. Cooper MJ, Haluschak JJ, Johsond D, Schwartz S, Morrison LJ, Lippa M, Hatzivassiliou G, Tan J. p53 mutations in bladder carcinoma cell lines. Oncol Res 1994;6:569-79
31. Scudiero PA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48:4827-33
32. Barton BE, Karras JG, Murphy TF, Barton A, Huang HF. Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 2004;3:11-20 (Pubitemid 39193674)
33. Kuo YC, Kuo PL, Hsu YL, Cho CY, Lin CC. Ellipticine induces apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells. Life Sci 2006;78:2550-7
34. Xu Z, Choudhary S, Voznesensky O, Mehrotra M, Woodard M, Hansen M, Herschman H, Pilbeam C. Overexpression of COX-2 in human osteosarcoma cells decreases proliferation and increases apoptosis. Cancer Res 2006;66:6657-64
35. Wang CCC, Chiang Y-M, Kuo P-L, Chang JK, Hsu YL. Norsolorinic acid inhibits proliferation of T24 human bladder cancer cells by arresting the cell cycle at the G0/G1 phase and inducing a fas/membrane-bound fas ligand-mediated apoptotic pathway. Clin Exp Pharmacol Physiol 2008;35:1301-8
36. Chou TC, Talalaly P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55
37. El-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol 1998;8:345-57
38. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995;11:1217-28
39. Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP, Leichman CG. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 1998;4:1243-50
40. Brandford CR, Zhus S, Ogawa H, Ogawa T, Ubell M, Narayan A, Johnson G, Wolf GT, Fisher SG, Carey TE. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 2003;25:654-61
41. Gallangher WM, Cairney M, Schott B, Roninson IB, Brown R. Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene 1997;14:185-93
42. Wang X, Wong SC, Pan J, Tsao SW, Fung KH, Kwong DL, Sham JS, Nicholls JM. Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells. Cancer Res 1998;58:5019-22
43. Roberts JJ, Pascoe JM. Cross-linking of complementary strands of DNA in mammalian cells by antitumour platinum compounds. Nature 1972;235:282-4
44. Weiss RB, Christian MC. New cisplatin analogues in development. A review. Drugs 1993;46:360-77
45. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104:263-269
46. Lapouge G, Millon R, Muller D, Abecassis J, Eber M, Bergerat JP, Klein-Soyer C. Cisplatin-induced genes as potential markers for thyroid cancer. Cell Mol Life Sci 2005;62:53-64 (Pubitemid 40933092)
47. Merlin T, Brander G, Hess RD. Cell cycle arrest in ovarian cancer cell lines does not depend on p53 status upon treatment with cytostatic drugs. Int J Oncol 1998;13:1007-16 (Pubitemid 28506071)
48. Paulwels B, Korst AE, Andriessen V, Baay MF, Pattyn GG, Lambrechts HA, Pooter CM, Lardon F, Vermorken JB. Unraveling the mechanism of radiosensitization by gemcitabine: the role of TP53. Radiat Res 2005;164:642-50 (Pubitemid 41532559)
49. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang ZF, Rosai J, Reuter VE, Pellicer A. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 1994;56:347-53 (Pubitemid 2041219)
50. Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Res Updates 2002;5:19-33
51. Tannock IF, Lee C. Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs. Br J Cancer 2001;84:100-5 (Pubitemid 32102512)
52. Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Res Updates 2002;5:19-33
53. Theodossiou C, Cook JA, Fisher J, Teague D, Liebmann JE, Russo A, Mitchell JB. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell line. Int J Oncol 1998;12:825-32 (Pubitemid 28133574)
54. van Moorsel CJ, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, van der Vijgh WJ, Peters GJ. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 1999;80:981-90 (Pubitemid 29065289)
55. Slaton JW, Benedict WF, Dinney CP. P53 in bladder cancer: mechanism of action, prognostic value, and target for therapy. Urology 2001;57:852-9